A fifth NOAC, betrixaban, has not been approved by the FDA for use in patients with AF. Antithrombotic (anticoagulant combined with antiplatelet) therapy is discussed in Sections 4.4.1. and 7.4. (S4.1.1-4). Recommendations for Selecting an Anticoagulant Regimen—Balancing Risks and Benefits ...
Some third parties are outside of the European Economic Area, with varying standards of data protection. See our privacy policy for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies ...
Screening for Depression, Anxiety, and Suicide Risk in Adults: A Systematic Evidence Review for the US Preventive Services Task Force. Evidence Synthesis No. 223. Agency for Healthcare Research and Quality; 2023. AHRQ publication 22-05295-EF-1. 8. O’Connor E, Rossom RC, Henninger ...